½ÃÀ庸°í¼­
»óǰÄÚµå
1510745

À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå : Áö¿ªº° ºÐ¼® : À¯Çü, ¿ëµµ, À¯Åë ä³Îº° ¿¹Ãø(2030³â)

Europe Transdermal Drug Delivery System Market Forecast to 2030 - Regional Analysis - by Type, Application, and Distribution Channel

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2022³â 104¾ï 3,386¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 144¾ï 2,286¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 4.1%·Î ÃßÁ¤µË´Ï´Ù.

ºñħ½À ¾à¹°Àü´Þ ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ À¯·´ÀÇ °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀ» µÞ¹Þħ

±ÙÀ° ³», Á¤¸Æ ³», Á÷Àå Åõ¿©¿Í °°Àº ÀüÅëÀûÀÎ ¾à¹° Àü´Þ ±â¼úÀº ÁÖ·Î ÅëÁõ°ú º¹À⼺À» ¼ö¹ÝÇϱ⠶§¹®¿¡ ƯÁ¤ ȯÀÚÃþ¿¡°Ô´Â ¼±È£µÇÁö ¾Ê½À´Ï´Ù. ÀÇ·á ¹× ¾à¹° Àü´Þ ±â¼úÀÇ Áøº¸·Î ºñħ½ÀÀû ¾à¹° Àü´Þ ½Ã½ºÅÛÀº ±âÁ¸ Áֻ翡 ÀÇÇÑ ¾à¹° Åõ¿©¿Í °æÀïÇÏ°Ô µÇ¾ú½À´Ï´Ù. ºñħ½ÀÀû ¾à¹° Àü´Þ ½Ã½ºÅÛÀº °æ±¸¾à, ±¹¼Ò¾à, °æÇÇÈí¼öÁ¦(ÀåÄ¡¿¡ ÀÇÇÑ Ä§Åõ ÃËÁø), °æÇÇÈí¼öÁ¦, °æ¾È¸·¾à, °æÁ¡¸·¾à, ÈíÀÔÁ¦¿¡ ÀÇÇÑ ÆóÆ÷¸·¾à µîÀ» Æ÷ÇÔÇÕ´Ï´Ù. °æÇÇ ¾à¹° Àü´ÞÀº °æ±¸ Åõ¿©¿¡ ºñÇØ ¿©·¯¸é¿¡¼­ À¯¸®ÇÕ´Ï´Ù. ƯÈ÷ °æÇÇ Åõ¿©´Â ¾à¹°À» Ãæµ¿ÀûÀ¸·Î ´ë»çÇÏ´Â °£ÀÇ Ã¹ ¹øÂ° Åë°ú ¸ÞÄ¿´ÏÁòÀ» ÇÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, °æÇÇ Åõ¿©´Â ÇÇÇÏ Áֻ縸ŭ °íÅ뽺·´Áö ¾ÊÀ¸¸ç, ÀÌ °æ·Î¿¡¼­´Â À§ÇèÇÑ ÀÇ·á Æó±â¹°µµ ³ªÅ¸³ªÁö ¾ÊÀ¸¸ç, ƯÈ÷ °³¹ßµµ»ó±¹À̳ª Àú°³¹ß ±¹°¡¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Â ÁÖ»ç ¹Ù´ÃÀÇ Àç»ç¿ë¿¡ ÀÇÇÑ Áúº´ ÀüÆÄÀÇ À§Çèµµ ¾ø½À´Ï´Ù ÀÔ´Ï´Ù. °Ô´Ù°¡, ºñħ½ÀÀûÀÎ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛÀº Åõ¿© ½ºÄÉÁÙÀ» ´Ü¼øÈ­Çϰí, ¾à¹°ÀÇ ÀÚ°¡ Åõ¿©°¡ °¡´ÉÇÕ´Ï´Ù. ºñħ½ÀÀûÀ¸·Î ¾à¹°À» Åõ¿©ÇÏ´Â °æ¿ì ÅëÁõÀÌ Àû°Å³ª ÀüÇô ¾ø±â ¶§¹®¿¡ ȯÀÚÀÇ ÄÄÇöóÀ̾𽺰¡ ÈξÀ ³ô¾ÆÁý´Ï´Ù. µû¶ó¼­, ÀÌ °æ·Î´Â ¾à¹°Àü´ÞÀÇ ¹Ù¶÷Á÷ÇÑ ¸ðµå·Î »ý°¢µË´Ï´Ù. ¶ÇÇÑ, ºñħ½ÀÀû ¾à¹° Àü´Þ ½Ã½ºÅÛÀº ȯÀÚ¿¡ ÀÇÇÑ ¾à¹°ÀÇ ÀÚ°¡ Åõ¿©·Î ÀÎÇØ ÀÓ»ó »ç¿ë ºñ¿ëÀ» ´ëÆø Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ¿¡ ÀÇÇØ ÃËÁøµÇ´Â ºñ ħ½ÀÀû ¾à¹° Àü´Þ°ú °ü·ÃµÈ ÀÌÁ¡Àº ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀ̵Ǿú½À´Ï´Ù.

À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå °³¿ä

À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº ¿µ±¹, ÇÁ¶û½º, µ¶ÀÏ, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ ¹× ±âŸ À¯·´ÀÇÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â µ¶ÀÏÀº À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀº ÅëÁõ °ü¸®ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí Áö¿ª¿¡¼­ ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó »ó´çÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ½ÉºÎÀü, ½É±Ù°æ»ö, °ü»óµ¿¸Æ¼º ½ÉÀå Áúȯ, ¿°Áõ¼º ½ÉÀå Áúȯ µîÀÇ ½ÉÇ÷°ü ÁúȯÀº ÀÌ Áö¿ª¿¡¼­ °¡Àå ±¤¹üÀ§ÇÑ °Ç°­ ¹®Á¦¸¦ Â÷ÁöÇÕ´Ï´Ù. µ¶ÀÏÀº ÀÇ·á ÀÇ·á ºÎ¹®¿¡¼­ ±¹°¡¸¦ ÃÖÀü¼±À¸·Î À̲ô´Â ±â¼úÀÇ ¹ßÀüÀ¸·Î À¯¸íÇÕ´Ï´Ù. 2021³â ±¹¸³»ý¹°°øÇÐÁ¤º¸¼¾ÅÍ(NCBI)¿¡¼­ ¹ßÇ¥µÈ ¿¬±¸¿¡ µû¸£¸é ½ÉÇ÷°ü°è ÁúȯÀÇ À¯º´·üÀº µ¿µ¶¿¡¼­ ³ôÀº °æ¿ì°¡ ¸¹´Ù°í ÇÕ´Ï´Ù. ÀÌ ³ª¶ó¿¡¼­´Â ÃÖ±Ù ½ÃÀå °ü°èÀÚ¿¡ ÀÇÇÑ ±â¼ú Çõ½Åµµ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. 2023³â 5¿ù, Bionext Solutions´Â ÆÄŲ½¼º´ Ä¡·á¸¦ À§ÇØ ¼³°èµÈ °æÇÇ ·ÎƼ°íƾ ÆÐÄ¡ÀÇ ¾à¹° Èí¼ö ºñ±³ ½ÃÇèÀ» ÁøÇàÇϱâ À§ÇÑ Á¤ºÎ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌ È¸»ç´Â ºÏ¹ÌÀÇ¿Í À¯·´ÀÇ¿¡ ¿¬±¸ °³¹ß °ÅÁ¡À» °¡Áö°í ÀÖÀ¸¸ç µ¶ÀÏÀ» Áß½ÉÀ¸·Î »ç¾÷À» Àü°³Çϰí ÀÖÀ¸¸ç ÇöÀç À¯·´ÀÇ ½ÃÀå¿ë ÀÇ·á Á¦Ç°ÀÇ ¾à»ç ½ÂÀÎ ¹× »ó¾÷È­¸¦ ÃßÁøÇϰí ÀÖ½À´Ï´Ù.

2019³â 3¿ù, LTS Lohmann Therapie - Systeme AG¿Í LEO Pharma A/S´Â °øµ¿À¸·Î °Ç¼±ÀÇ ±¹¼Ò Çdz» Ä¡·á¸¦ À§ÇÑ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ÆÐÄ¡ÀÇ ÀÓ»ó½ÃÇèÀ» ½ÃÀÛÇß½À´Ï´Ù.

µ¶ÀÏÀº ÀÇ·á Á¦Ç°°ú ¼­ºñ½º¸¦ ¼öÃâÇÏ´Â ÁÖ¿ä ±¹°¡ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ ±â¼úÀû Áøº¸¶ó´Â ÀÚ»êÀÌ Ç°Áú, ¾ÈÀü¼º, ½Å·Ú¼ºÀÇ ±¹Á¦ ±âÁØÀ» Á¤Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ðµç °Ç°­ ¹× ÀÇ·á ºÎ¹®¿¡¼­ µ¶ÀÏ Á¦Á¶¾÷ü ¹× ¼­ºñ½º Á¦°ø¾÷ü´Â ÀÇ·á Çõ½ÅÀ» Á¦°øÇÔÀ¸·Î½á ÇØ¿Ü °í°´°ú ÆÄÆ®³Ê¸¦ ¸Å·á½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æÇÇ ÆÐÄ¡ÀÇ °³Ã´Àº µ¶ÀÏ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå ¼öÀͰú ¿¹Ãø(-2030³â)(±Ý¾×)

À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼¼ºÐÈ­

À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº À¯Çü, ¿ëµµ, À¯Åë ä³Î, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.

À¯Çüº°·Î À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº °æÇÇ ÆÐÄ¡, °æÇÇ Á©, °æÇÇ ½ºÇÁ·¹ÀÌ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼­´Â °æÇÇ °Ö ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. °æÇÇ ÆÐÄ¡´Â ¶ÇÇÑ ¾à¹° Á¢Âø ÆÐÄ¡, ¸ÅÆ®¸¯½º ÆÐÄ¡, ÀúÀå¼Ò ¸· ÆÐÄ¡, Áõ±â ÆÐÄ¡·Î ¼¼ºÐÈ­µË´Ï´Ù.

¿ëµµº°·Î À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº ½ÉÇ÷°ü Áúȯ, ÁßÃß ½Å°æ Àå¾Ö, ÅëÁõ °ü¸®, È£¸£¸ó ¿ëµµ ¹× ±âŸ ¿ëµµ·Î ºÐ·ùµË´Ï´Ù. ÅëÁõ °ü¸® ºÎ¹®Àº 2022³â À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÅëÁõ °ü¸®´Â ¶ÇÇÑ ¿ÀÇÇ¿ÀÀ̵å¿Í ºñ ¿ÀÇÇ¿ÀÀ̵å·Î ¼¼ºÐÈ­µË´Ï´Ù. È£¸£¸ó ¾ÖÇø®ÄÉÀ̼ÇÀº ¶ÇÇÑ °æÇÇ ¿¡½ºÆ®·Î°Õ ¹× ÇÁ·Î°Ô½ºÅ×·Ð Ä¡·á¿Í Å×½ºÅ佺Å×·Ð º¸ÃæÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù.

À¯Åë ä³Îº°·Î À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼­ º´¿ø ¾à±¹ ºÎ¹®Àº °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù.

±¹°¡º°·Î º¼ ¶§ À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº ¿µ±¹, ÇÁ¶û½º, µ¶ÀÏ, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ ¹× ±âŸ À¯·´ÀÇÀ¸·Î ºÐ·ùµË´Ï´Ù. 2022³â À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº µ¶ÀÏÀÌ µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, UCB SA, Viatris Inc´Â À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µ ´ë±â¾÷ÀÇ ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ÁÖ¿ä »ê¾÷ ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡
    • ºñħ½À ¾à¹°Àü´Þ µð¹ÙÀ̽º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • ¾àÁ¦ÀÇ ÀÚ±â Åõ¿©¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ºÎÀÛ¿ë°ú ¸®ÄÝ
  • ½ÃÀå ±âȸ
    • ½º¸¶Æ® ÆÐÄ¡¿Í 3D ÇÁ¸°ÆÃ ÆÐÄ¡ÀÇ Áøº¸
  • ÇâÈÄÀÇ µ¿Çâ
    • Á¦Á¶¾÷ü¿¡ ÀÇÇÑ Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê
  • ¿µÇ⠺м®

Á¦5Àå °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå : À¯·´ÀÇ ½ÃÀå ºÐ¼®

  • °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ À¯·´ÀÇ ½ÃÀå ¸ÅÃâ¾× ¿¹Ãø±â°£ µ¿¾È

Á¦6Àå °æÇÇÀÇ ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ À¯·´ÀÇ ½ÃÀå : ¼öÀͰú ¿¹Ãø(-2030³â) À¯Çüº°

  • ¼Ò°³
  • À¯·´ °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå(2022³â ¹× 2030³â) : À¯Çüº° ¸ÅÃâ¾× Á¡À¯À²(%)
  • °æÇÇ ÆÐÄ¡
  • °æÇÇ °Ö
  • °æÇÇ ½ºÇÁ·¹ÀÌ
  • ±âŸ

Á¦7Àå À¯·´ÀÇ °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¼öÀͰú ¿¹Ãø(-2030³â) ¿ëµµº°

  • ¼Ò°³
  • À¯·´ °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå(2022³â ¹× 2030³â) : ¿ëµµº° ¸ÅÃâ¾× Á¡À¯À²(%)
  • ½ÉÇ÷°ü Áúȯ
  • ÁßÃß ½Å°æ°è Áúȯ
  • ÅëÁõ °ü¸®
  • È£¸£¸ó ¿ëµµ
  • ±âŸ

Á¦8Àå À¯·´ÀÇ °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¼öÀͰú ¿¹Ãø(-2030³â) À¯Åë ä³Îº°

  • ¼Ò°³
  • À¯·´ °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå(2022³â ¹× 2030³â) : À¯Åë ä³Îº° ¸ÅÃâ Á¡À¯À²(%)
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ±âŸ

Á¦9Àå À¯·´ÀÇ °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀå : ¼öÀͰú ¿¹Ãø(-2030³â) ±¹°¡º° ºÐ¼®

  • µ¶ÀÏ
  • ÇÁ¶û½º
  • ¿µ±¹
  • ÀÌÅ»¸®¾Æ
  • ½ºÆäÀÎ
  • ±âŸ À¯·´

Á¦10Àå °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå ¾÷°è Á¤¼¼

  • ¼Ò°³
  • °æÇÇ ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Novartis AG
  • Johnson & Johnson
  • GSK Plc
  • Viatris Inc
  • Boehringer Ingelheim International GmbH
  • Hisamitsu Pharmaceutical Co Inc
  • Luye Pharma Group Ltd
  • Lavipharm SA
  • UCB SA

Á¦12Àå ºÎ·Ï

BJH 24.07.18

The Europe transdermal drug delivery system market is expected to grow from US$ 10,433.86 million in 2022 to US$ 14,422.86 million by 2030. It is estimated to register a CAGR of 4.1% from 2022 to 2030.

Growing Demand for Noninvasive Drug Delivery Devices Fuels Europe Transdermal Drug Delivery System Market

Traditional drug delivery techniques such as intramuscular, intravenous, and rectal drug administration are not preferred by certain patient populations mainly due to the pain and complexities associated with them. With the improvements in medical science and definite drug delivery technologies, noninvasive drug delivery systems are now set to compete with the traditional method of injectable route of drug administration. The noninvasive drug delivery systems include drug delivery via oral; topical; transdermal-active (device-aided enhanced penetration) and transdermal-passive; and transocular membrane, transmucosal membrane, and alveolar membrane from inhaled medication. Transdermal drug delivery is advantageous in many ways over the oral route of administration. In particular, it evades the first-pass mechanism of the liver, which can otherwise impulsively metabolize drugs.

Further, transdermal delivery is not as painful as hypodermic injections, and this route leads to no dangerous medical waste and poses no risk of disease transmission by needle reuse, which is especially common in developing and under-developed countries. In addition, a noninvasive transdermal drug delivery system has simplified dosing schedules, and the drugs can be self-administered. Patient compliance is much higher when drugs are administrated noninvasively due to low or no pain involved. Therefore, this route is considered a preferred mode of drug delivery. Moreover, a non-invasive drug delivery system can significantly reduce the cost of clinical use because of the self-administration of the drugs by the patients. Thus, the advantages associated with a noninvasive drug delivery facilitated by transdermal drug delivery systems drive the market growth.

Europe Transdermal Drug Delivery System Market Overview

The Europe transdermal drug delivery system market is segmented into the UK, France, Germany, Spain, Italy, and the Rest of Europe. In 2022, the Germany held the largest share of the Europe transdermal drug delivery system market. The market is expected to grow significantly owing to the growing need for pain management and the increasing prevalence of cardiovascular diseases in the region. Cardiovascular diseases such as heart failure, myocardial infarction, coronary cardiac disease, and inflammatory heart disease account for the broadest health problems in the region. Germany is known for its advancement in technology that helps lead the country to the forefront in the medical and healthcare sectors. According to a study published in 2021 in the National Center for Biotechnology Information (NCBI), cardiovascular disease prevalence is often higher in East Germany. The country has also witnessed increasing innovations through market players in recent years. In May 2023, BioNxt Solutions Inc. received government approval to proceed with a comparative drug absorption study for a transdermal Rotigotine patch designed to treat Parkinson's disease. The company has R&D operations in North America and Europe, with an operational focus in Germany, and is currently undergoing regulatory approval and commercialization of medical products for European markets.

In March 2019, LTS Lohmann Therapie-Systeme AG and LEO Pharma A/S together started a clinical trial of microarray patches for the local intradermal treatment of psoriasis.

Germany is also among the primary countries that export healthcare products and services. In addition, the asset of technological advancement has set international standards for quality, safety, and reliability. Moreover, the German manufacturers and service providers in all health and medical segments fascinate foreign customers and partners by delivering healthcare innovation. Such developments in transdermal patches fuel the growth of the transdermal drug delivery system market in Germany.

Europe Transdermal Drug Delivery System Market Revenue and Forecast to 2030 (US$ Million)

Europe Transdermal Drug Delivery System Market Segmentation

The Europe transdermal drug delivery system market is segmented into type, application, distribution channel, and country.

Based on type, the Europe transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held the largest share of the Europe transdermal drug delivery system market in 2022. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.

In terms of application, the Europe transdermal drug delivery system market is categorized into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held the largest share of the Europe transdermal drug delivery system market in 2022. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.

By distribution channel, the Europe transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the Europe transdermal drug delivery system market in 2022.

Based on country, the Europe transdermal drug delivery system market is categorized into the UK, France, Germany, Spain, Italy, and the Rest of Europe. Germany dominated the Europe transdermal drug delivery system market in 2022.

Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, UCB SA, and Viatris Inc are some of the leading companies operating in the Europe transdermal drug delivery system market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Transdermal Drug Delivery System Market - Key Industry Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Increasing Prevalence of Chronic Diseases
    • 4.1.2 Growing Demand for Noninvasive Drug Delivery Devices
    • 4.1.3 High Demand for Self-Administration of Drugs
  • 4.2 Market Restraints
    • 4.2.1 Adverse Effects and Recall of Transdermal Drug Delivery Systems
  • 4.3 Market Opportunities
    • 4.3.1 Advancements in Smart Patches and 3D-Printed Patches
  • 4.4 Future Trends
    • 4.4.1 Strategic Initiatives by Manufacturers
  • 4.5 Impact Analysis

5. Transdermal Drug Delivery System Market - Europe Market Analysis

  • 5.1 Europe Transdermal Drug Delivery System Market Revenue (US$ Mn), 2022 - 2030

6. Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Type

  • 6.1 Overview
  • 6.2 Europe Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
  • 6.3 Transdermal Patches
    • 6.3.1 Overview
    • 6.3.2 Transdermal Patches: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.1 Drug-in-Adhesive Patches
        • 6.3.2.1.1 Overview
        • 6.3.2.1.2 Drug-in-Adhesive Patches: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.2 Matrix Patches
        • 6.3.2.2.1 Overview
        • 6.3.2.2.2 Matrix Patches: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.3 Reservoir Membrane Patches
        • 6.3.2.3.1 Overview
        • 6.3.2.3.2 Reservoir Membrane Patches: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 6.3.2.4 Vapor Patches
        • 6.3.2.4.1 Overview
        • 6.3.2.4.2 Vapor Patches: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Transdermal Gels
    • 6.4.1 Overview
    • 6.4.2 Transdermal Gels: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Transdermal Sprays
    • 6.5.1 Overview
    • 6.5.2 Transdermal Sprays: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Application

  • 7.1 Overview
  • 7.2 Europe Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
  • 7.3 Cardiovascular Diseases
    • 7.3.1 Overview
    • 7.3.2 Cardiovascular Diseases: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Central Nervous System Disorders
    • 7.4.1 Overview
    • 7.4.2 Central Nervous System Disorders: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Pain Management
    • 7.5.1 Overview
    • 7.5.2 Pain Management: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.5.2.1 Opioid
        • 7.5.2.1.1 Overview
        • 7.5.2.1.2 Opioid: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.5.2.2 Non-Opioid
        • 7.5.2.2.1 Overview
        • 7.5.2.2.2 Non-Opioid: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Hormonal Applications
    • 7.6.1 Overview
    • 7.6.2 Hormonal Applications: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.6.2.1 Transdermal Estrogen & Progesterone Therapy
        • 7.6.2.1.1 Overview
        • 7.6.2.1.2 Transdermal Estrogen & Progesterone Therapy: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.6.2.2 Testosterone Replacement
        • 7.6.2.2.1 Overview
        • 7.6.2.2.2 Testosterone Replacement: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Other Application
    • 7.7.1 Overview
    • 7.7.2 Other Application: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Distribution Channel

  • 8.1 Overview
  • 8.2 Europe Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • 8.3 Hospital Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Hospital Pharmacies: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Retail Pharmacies
    • 8.4.1 Overview
    • 8.4.2 Retail Pharmacies: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Online Pharmacies
    • 8.5.1 Overview
    • 8.5.2 Online Pharmacies: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - Country Analysis

  • 9.1 Europe Transdermal Drug Delivery System Market
    • 9.1.1 Europe Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
      • 9.1.1.1 Germany: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.1.1 Overview
        • 9.1.1.1.2 Germany: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.1.3 Germany: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
        • 9.1.1.1.3.1 Germany: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
        • 9.1.1.1.4 Germany: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
        • 9.1.1.1.4.1 Germany: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
        • 9.1.1.1.4.2 Germany: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
        • 9.1.1.1.5 Germany: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.1.2 France: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.2.1 Overview
        • 9.1.1.2.2 France: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.2.3 France: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
        • 9.1.1.2.3.1 France: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
        • 9.1.1.2.4 France: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
        • 9.1.1.2.4.1 France: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
        • 9.1.1.2.4.2 France: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
        • 9.1.1.2.5 France: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.1.3 UK: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.3.1 Overview
        • 9.1.1.3.2 UK: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.3.3 UK: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
        • 9.1.1.3.3.1 UK: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
        • 9.1.1.3.4 UK: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
        • 9.1.1.3.4.1 UK: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
        • 9.1.1.3.4.2 UK: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
        • 9.1.1.3.5 UK: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.1.4 Italy: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.4.1 Overview
        • 9.1.1.4.2 Italy: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.4.3 Italy: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
        • 9.1.1.4.3.1 Italy: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
        • 9.1.1.4.4 Italy: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
        • 9.1.1.4.4.1 Italy: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
        • 9.1.1.4.4.2 Italy: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
        • 9.1.1.4.5 Italy: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.1.5 Spain: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.5.1 Overview
        • 9.1.1.5.2 Spain: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.5.3 Spain: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
        • 9.1.1.5.3.1 Spain: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
        • 9.1.1.5.4 Spain: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
        • 9.1.1.5.4.1 Spain: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
        • 9.1.1.5.4.2 Spain: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
        • 9.1.1.5.5 Spain: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 9.1.1.6 Rest of Europe: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.6.1 Overview
        • 9.1.1.6.2 Rest of Europe: Europe Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.1.6.3 Rest of Europe: Europe Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
        • 9.1.1.6.3.1 Rest of Europe: Europe Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
        • 9.1.1.6.4 Rest of Europe: Europe Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
        • 9.1.1.6.4.1 Rest of Europe: Europe Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
        • 9.1.1.6.4.2 Rest of Europe: Europe Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
        • 9.1.1.6.5 Rest of Europe: Europe Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Transdermal Drug Delivery System Market Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Transdermal Drug Delivery System Market
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Organic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Novartis AG
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Johnson & Johnson
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 GSK Plc
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Viatris Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Boehringer Ingelheim International GmbH
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Hisamitsu Pharmaceutical Co Inc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Luye Pharma Group Ltd
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Lavipharm SA
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 UCB SA
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦